[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:post-transplant-lymphoproliferative-disorder":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":64,"states":65},"Post-Transplant Lymphoproliferative Disorder",8,4,[8,16,23,30,36,44,50,57],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06954805","Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)",[12],"Phase 2","RECRUITING","2026-08-26T02:17:52.450442Z","2026-05-05T02:43:29.355601Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT03394365","A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy",[20],"Phase 3","2026-08-26T02:19:11.399072Z","2026-05-05T02:43:26.675337Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT06672705","Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders",[27],"Phase 1","2026-08-26T02:18:58.141497Z","2026-05-05T02:35:31.915210Z",{"nct_id":31,"title":32,"phases":33,"status":13,"updated_at":34,"content_modified":35},"NCT06723457","Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma",[12],"2026-08-26T02:17:54.420226Z","2026-07-19T19:36:05.137870Z",{"nct_id":37,"title":38,"phases":39,"status":41,"updated_at":42,"content_modified":43},"NCT07573436","Loncastuximab Tesirine and Rituximab as First-line Therapy in Patients With Post-transplant Lymphoproliferative Disorder (PLUTO)",[40],"Phase 1\u002FPhase 2","NOT_YET_RECRUITING","2026-08-26T02:18:22.309547Z","2026-05-13T02:55:06.779367Z",{"nct_id":45,"title":46,"phases":47,"status":41,"updated_at":48,"content_modified":49},"NCT07517705","MRD-Adapted Low-Dose Radiation Therapy During Frontline Chemoimmunotherapy for Diffuse Large B-Cell Lymphoma",[12],"2026-08-26T02:15:39.267524Z","2026-06-16T05:54:07.939905Z",{"nct_id":51,"title":52,"phases":53,"status":54,"updated_at":55,"content_modified":56},"NCT06027879","Anti-viral T-cell Therapy by Gamma Capture",[40],"ENROLLING_BY_INVITATION","2026-08-26T02:17:35.666428Z","2026-06-16T05:54:08.096276Z",{"nct_id":58,"title":59,"phases":60,"status":61,"updated_at":62,"content_modified":63},"NCT06040320","Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD)",[40],"ACTIVE_NOT_RECRUITING","2026-08-03T02:35:33.342592Z","2026-05-05T02:43:28.121863Z",[],[66],{"state":67,"count":68,"slug":69},"Missouri",3,"missouri"]